Roche Holding AG (ROG.VX)

ROG.VX on Virt-X Level 1

278.00CHF
24 Oct 2014
Price Change (% chg)

CHF-1.40 (-0.50%)
Prev Close
CHF279.40
Open
CHF279.40
Day's High
CHF279.40
Day's Low
CHF276.60
Volume
1,181,668
Avg. Vol
1,279,204
52-wk High
CHF285.50
52-wk Low
CHF231.20

ROG.VX

Chart for ROG.VX

About

Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. It belongs to the Roche Group that operates through subsidiaries and associated companies. It discovers, develops and provides diagnostic and therapeutic products and services from early detection and prevention of diseases to diagnosis, treatment... (more)

Overall

Beta: 0.89
Market Cap (Mil.): CHF239,456.00
Shares Outstanding (Mil.): 862.56
Dividend: 7.80
Yield (%): 2.79

Financials

  ROG.VX Industry Sector
P/E (TTM): 22.40 33.08 33.86
EPS (TTM): 12.47 -- --
ROI: 26.39 18.26 17.53
ROE: 68.57 18.93 18.34
Search Stocks

BUZZ-Pacific Biosciences of California Inc: Q3 loss narrows

** Reports narrower-than-expected quarterly loss helped by higher sales of its gene sequencing systems

11:24am EDT

UPDATE 2-Roche to spend $3.2 billion on towering Basel base

* To build new R&D centre, office tower, renovate buildings

22 Oct 2014

Roche to spend $3.2 billion on Basel site upgrade

ZURICH - Swiss drugmaker Roche said on Wednesday it would spend 3 billion Swiss francs ($3.2 billion) to upgrade its Basel site, a vote of confidence in its Swiss base despite ongoing uncertainty over the country's immigration laws.

22 Oct 2014

Petition calls on Roche to cut breast cancer drug price

LONDON - A British-led petition signed by 29,000 people has demanded that Switzerland's Roche, the world's biggest maker of cancer medicines, cut the price of its expensive new breast cancer drug Kadcyla.

21 Oct 2014

Petition calls on Roche to cut breast cancer drug price

LONDON, Oct 21 - A British-led petition signed by 29,000 people has demanded that Switzerland's Roche, the world's biggest maker of cancer medicines, cut the price of its expensive new breast cancer drug Kadcyla.

21 Oct 2014

NewLink in $1 billion deal with Roche to develop cancer drug

- NewLink Genetics Corp said it entered into an agreement with Roche Holding AG to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments.

20 Oct 2014

UPDATE 1-NewLink in $1 bln deal with Roche to develop cancer drug

Oct 20 - NewLink Genetics Corp said it entered into an agreement with Roche Holding AG to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments.

20 Oct 2014

NewLink in $1 bln deal with Roche to develop cancer drug

Oct 20 - NewLink Genetics Corp said it entered into a licensing agreement with Roche Holding AG to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments.

20 Oct 2014

Roche, Merck extend immunotherapy fight to breast cancer

LONDON - Swiss drugmaker Roche and U.S. group Merck & Co are to present data on their rival immunotherapy drugs in breast cancer in December, extending the novel approach to fighting tumors to another cancer type.

17 Oct 2014

Roche, Merck extend immunotherapy fight to breast cancer

LONDON - Swiss drugmaker Roche and U.S. group Merck & Co are to present data on their rival immunotherapy drugs in breast cancer in December, extending the novel approach to fighting tumours to another cancer type.

17 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks